Zhong XC, Wang X. Endothelial cell-derived exosomes: A natural shield against osteoblast ferroptosis in diabetes. World J Diabetes 2026; 17(9): 117497 [DOI: 10.4239/wjd.117497]
Corresponding Author of This Article
Xia Wang, Associate Professor, Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241 Huaihai West Road, Xuhui District, Shanghai 200030, China. wangxia31610@163.com
Research Domain of This Article
Cell Biology
Article-Type of This Article
editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zhong XC, Wang X. Endothelial cell-derived exosomes: A natural shield against osteoblast ferroptosis in diabetes. World J Diabetes 2026; 17(9): 117497 [DOI: 10.4239/wjd.117497]
World J Diabetes. Sep 15, 2026; 17(9): 117497 Published online Sep 15, 2026. doi: 10.4239/wjd.117497
Endothelial cell-derived exosomes: A natural shield against osteoblast ferroptosis in diabetes
Xiao-Cheng Zhong, Xia Wang
Xiao-Cheng Zhong, Xia Wang, Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
Xiao-Cheng Zhong, Department of Cardiology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, Fujian Province, China
Author contributions: Zhong XC contributed to this manuscript; Wang X designed the overall concept and outline of the manuscript. All authors reviewed and approved the final draft of the paper.
AI contribution statement: The entirety or any portion of the Main Text was not AI-generated. The content was authored by the humans; AI was only used for assistance for language polishing and grammar correction.
Supported by National Natural Science Foundation of China, No. 82570522.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Xia Wang, Associate Professor, Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241 Huaihai West Road, Xuhui District, Shanghai 200030, China. wangxia31610@163.com
Received: December 10, 2025 Revised: December 25, 2025 Accepted: January 12, 2026 Published online: September 15, 2026 Processing time: 264 Days and 23.5 Hours
Core Tip
Core Tip: Diabetic osteoporosis (DOP), a common diabetic complication lacking targeted treatments, stems from chronic hyperglycemia disrupting the bone microenvironment. Key pathophysiological mechanisms include the accumulation of advanced glycation end products, oxidative stress, inflammation, and cell death. Currently, the field of DOP is moving beyond bone mineral density to understand the molecular and cellular dysregulation at the bone-vascular interface, aiming for precise diagnostics and therapies. This editorial highlight endothelial cell-derived exosomes and their cargo microRNA-335-3p as emerging and critical players in the pathophysiology of DOP. It discusses their role in inhibiting osteoclast ferroptosis and alleviating bone loss, while also identifying serum microRNA-335-3p as a promising non-invasive biomarker for early detection and monitoring, bridging molecular mechanisms with clinical translation.
